Asset profile
BCD-132
Monoclonal antibody
Evidence outlook · lead readout
MIRANTIBUS (NCT05385744) · Multiple Sclerosis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
MIRANTIBUS (NCT05385744): Randomized, double-blind, active-controlled Phase 3 trial (n=480) showing superior relapse reduction vs teriflunomide (PMID 38676683).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
51 competitors in this universe: 8 direct rivals (same mechanism and indication), 7 same-class, 36 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BCD-132: this drug | Phase 3 | Monoclonal antibody | CD20 | ||
| Ocrelizumab | Approved | Monoclonal antibody | CD20 | ||
| Ocrevus Zunovo | Approved | Monoclonal antibody | CD20 | ||
| Ofatumumab | Approved | Monoclonal antibody | CD20 | ||
| Ublituximab | Approved | Monoclonal antibody | CD20 | ||
| ABP 692 | Phase 3 | Monoclonal antibody | CD20 | ||
| BCD-281 | Phase 3 | Monoclonal antibody | CD20 | ||
| CT-P53 | Phase 3 | Monoclonal antibody | CD20 | ||
| Divozilimab | Phase 3 | Monoclonal antibody | CD20 | ||
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | ||
| Rituximab | Approved | Monoclonal antibody | CD20, CD20-directed Cytolytic Antibody | ||
| Acellbia | Phase 3 | Monoclonal antibody | CD20 | ||
| CT-P10 | Phase 3 | Monoclonal antibody | CD20 | ||
| HLX01 | Phase 3 | Monoclonal antibody | CD20 | ||
| MIL62 | Phase 3 | Monoclonal antibody | CD20 | ||
| SAR448501 | Phase 1 | Multispecific antibody | CD20 |
…and 36 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.